161 related articles for article (PubMed ID: 33315334)
1. Estimating the economic burden of migraine on US employers.
Yucel A; Thach A; Kumar S; Loden C; Bensink M; Goldfarb N
Am J Manag Care; 2020 Dec; 26(12):e403-e408. PubMed ID: 33315334
[TBL] [Abstract][Full Text] [Related]
2. Four-year review of presenteeism data among employees of a large United States health care system: a retrospective prevalence study.
Allen D; Hines EW; Pazdernik V; Konecny LT; Breitenbach E
Hum Resour Health; 2018 Nov; 16(1):59. PubMed ID: 30413168
[TBL] [Abstract][Full Text] [Related]
3. Burden of migraine in the United States: disability and economic costs.
Hu XH; Markson LE; Lipton RB; Stewart WF; Berger ML
Arch Intern Med; 1999 Apr; 159(8):813-8. PubMed ID: 10219926
[TBL] [Abstract][Full Text] [Related]
4. Economic burden of migraine in Latvia and Lithuania: direct and indirect costs.
Lublóy Á
BMC Public Health; 2019 Sep; 19(1):1242. PubMed ID: 31500616
[TBL] [Abstract][Full Text] [Related]
5. Productivity loss and productivity loss costs to United States employers due to priority conditions: a systematic review.
Rojanasarot S; Bhattacharyya SK; Edwards N
J Med Econ; 2023; 26(1):262-270. PubMed ID: 36695516
[TBL] [Abstract][Full Text] [Related]
6. Indirect cost burden of migraine in the United States.
Hawkins K; Wang S; Rupnow MF
J Occup Environ Med; 2007 Apr; 49(4):368-74. PubMed ID: 17426520
[TBL] [Abstract][Full Text] [Related]
7. The economic burden of lost productivity due to migraine headache: a specific worksite analysis.
Burton WN; Conti DJ; Chen CY; Schultz AB; Edington DW
J Occup Environ Med; 2002 Jun; 44(6):523-9. PubMed ID: 12085478
[TBL] [Abstract][Full Text] [Related]
8. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace.
Shimizu T; Sakai F; Miyake H; Sone T; Sato M; Tanabe S; Azuma Y; Dodick DW
J Headache Pain; 2021 Apr; 22(1):29. PubMed ID: 33882816
[TBL] [Abstract][Full Text] [Related]
9. Productivity cost benefit to employers of treating migraine with rizatriptan: a specific worksite analysis and model.
Gerth WC; Sarma S; Hu XH; Silberstein SD
J Occup Environ Med; 2004 Jan; 46(1):48-54. PubMed ID: 14724478
[TBL] [Abstract][Full Text] [Related]
10. Indirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the United States.
Patel JG; Nagar SP; Dalal AA
Int J Chron Obstruct Pulmon Dis; 2014; 9():289-300. PubMed ID: 24672234
[TBL] [Abstract][Full Text] [Related]
11. Productivity losses attributable to headache, and their attempted recovery, in a heavy-manufacturing workforce in Turkey: implications for employers and politicians.
Selekler HM; Gökmen G; Alvur TM; Steiner TJ
J Headache Pain; 2015; 16():96. PubMed ID: 26573819
[TBL] [Abstract][Full Text] [Related]
12. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
[TBL] [Abstract][Full Text] [Related]
13. Indirect costs attributed to headache: A nation-wide survey of an active working population.
Gil-Gouveia R; Miranda R
Cephalalgia; 2022 Apr; 42(4-5):317-325. PubMed ID: 34521261
[TBL] [Abstract][Full Text] [Related]
14. Migraine disorder: workplace implications and solutions.
Berry PA
AAOHN J; 2007 Feb; 55(2):51-6. PubMed ID: 17323870
[TBL] [Abstract][Full Text] [Related]
15. The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.
Ivanova JI; Birnbaum HG; Samuels S; Davis M; Phillips AL; Meletiche D
Pharmacoeconomics; 2009; 27(8):681-91. PubMed ID: 19712010
[TBL] [Abstract][Full Text] [Related]
16. United States Patients' Perspective of Living With Migraine: Country-Specific Results From the Global "My Migraine Voice" Survey.
Gibbs SN; Shah S; Deshpande CG; Bensink ME; Broder MS; Dumas PK; Buse DC; Vo P; Schwedt TJ
Headache; 2020 Jul; 60(7):1351-1364. PubMed ID: 32369201
[TBL] [Abstract][Full Text] [Related]
17. Healthcare resource use and indirect costs associated with migraine in Italy: results from the
Martelletti P; Schwedt TJ; Vo P; Ritrovato D; Reilly MC; Naclerio M; Ranjan P; Kleebach J; Joshi P
J Med Econ; 2021; 24(1):717-726. PubMed ID: 33955821
[TBL] [Abstract][Full Text] [Related]
18. Productivity Losses Due to Migraine in Slovenia: An Analysis of Absenteeism and Presenteeism Costs Based on Administrative and Self-Reported Data.
Lotrič Dolinar A; Žvan B; Došenović Bonča P
Zdr Varst; 2020 Jun; 59(2):75-82. PubMed ID: 32952706
[TBL] [Abstract][Full Text] [Related]
19. The hidden costs of employee drinking: A quantitative analysis.
Sullivan T; Edgar F; McAndrew I
Drug Alcohol Rev; 2019 Jul; 38(5):543-553. PubMed ID: 31170328
[TBL] [Abstract][Full Text] [Related]
20. Company reference estimates for productivity loss due to migraine and productivity gains using rizatriptan 10 mg in Germany.
Yoon MS; Katsarava Z; Liedert B; Krobot KJ; Diener HC; Limmroth V
Int J Clin Pract; 2006 Mar; 60(3):295-9. PubMed ID: 16494644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
